 Clover Biopharmaceuticals has reported positive data for their COVID-19 vaccine candidate, SCB-2019, which achieved the primary and secondary efficacy endpoints in SPECTRA Phase 23 clinical trial. The protein-based vaccine is adjuvanted with Dynavax Technologies Corporations NASDAQ: DVAX CpG 1018 adjuvant. 